down arrow

Solasia Pharma KK

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3436500007
  • TKS: 4597
JPY
31.00
1 (3.33%)

Sep 18

TKS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
RaQualia Pharma, Inc.
Fuso Pharmaceutical Industries Ltd.
Wakamoto Pharmaceutical Co., Ltd.
Healios KK
Taiko Pharmaceutical Co., Ltd.
Solasia Pharma KK
SymBio Pharmaceuticals Ltd.
Nippon Chemiphar Co., Ltd.
CanBas Co., Ltd.
BrightPath Biotherapeutics Co., Ltd.
Noile-Immune Biotech, Inc.

Why is Solasia Pharma KK ?

1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -229.10
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -229.10
2
Poor long term growth as Operating profit has grown by an annual rate 12.40% of over the last 5 years
3
Negative results in Jun 26
  • OPERATING CASH FLOW(Y) Lowest at JPY -1,140 MM
  • INTEREST(Q) At JPY 6 MM has Grown at 50%
  • RAW MATERIAL COST(Y) Grown by 1,870.05% (YoY)
4
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -8.82%, its profits have risen by 53.6%
5
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -8.82% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Solasia Pharma KK for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Solasia Pharma KK
-100.0%
0.30
63.38%
Japan Nikkei 225
43.52%
1.48
29.43%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
1.06%
EBIT Growth (5y)
12.40%
EBIT to Interest (avg)
-218.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.23
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.68
EV to EBIT
-5.47
EV to EBITDA
-5.70
EV to Capital Employed
27.94
EV to Sales
11.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-510.59%
ROE (Latest)
-52.17%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
NET PROFIT(HY)

Higher at JPY -579 MM

NET SALES(9M)

Higher at JPY 346 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 16.17 times

-18What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at JPY -1,140 MM

INTEREST(Q)

At JPY 6 MM has Grown at 50%

RAW MATERIAL COST(Y)

Grown by 1,870.05% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.21 times

NET SALES(Q)

Lowest at JPY 2 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -12,800 %

Here's what is working for Solasia Pharma KK

Net Profit
Higher at JPY -579 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Debtors Turnover Ratio
Highest at 16.17 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Solasia Pharma KK

Net Sales
At JPY 2 MM has Fallen at -91.67%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Operating Cash Flow
Lowest at JPY -1,140 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (JPY MM)

Interest
At JPY 6 MM has Grown at 50%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales
Lowest at JPY 2 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (JPY MM)

Operating Profit Margin
Lowest at -12,800 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Inventory Turnover Ratio
Lowest at 1.21 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost
Grown by 1,870.05% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading